PODD
Insulet CorpPrice & Indicators
Blended from price, positioning & fundamentals · daily-close · not investment advice.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| adjusted EPS growth non-GAAP | 40% | first quarter 2026 call | — |
| net access improvement | 4% | first quarter 2026 call | — |
| Estimated active Omnipod users globally | 600,000 | Full Year 2025 | — |
| Free cash flow non-GAAP | $377.7M | Full Year 2025 | — |
| Shares available under the repurchase program | $415M | as of February 16, 2026 | — |
| Shares repurchased under the repurchase program | $60M | as of February 16, 2026 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PODD
this stock
Insulet Corp
|
$11.39B | -42.1% | +30.7% | 38.4 | 7.1% |
|
ABT
Abbott Laboratories
|
$166.57B | -23.3% | +5.7% | 26.8 | 1.3% |
|
SYK
Stryker Corp
|
$124.49B | -7.4% | +11.2% | 37.6 | 1.6% |
|
MDT
Medtronic plc
|
$106.32B | -12.8% | +8.4% | 22.3 | 1.4% |
|
BSX
Boston Scientific Corp
|
$66.29B | -53.2% | +5.5% | 18.7 | 2.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PODD | +6.9% | +14.8% | -43.8% | +8.0% | -42.1% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +5.5% | +16.0% | -51.9% | +8.3% | -51.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.